Press Releases

Neura Therapeutik to Accelerate Development of Safe and Affordable Abuse-Deterrent Opioids
April 17, 2013
Neura Therapeutik announced today that they will be accelerating the development of their abuse‐deterrent... Read more

Abuse Deterrent Opioid from Neura Therapeutik Complies with FDA Draft Guidance
January 14, 2013
Neura Therapeutik announced today the securing of terms on NL-001, an abuse-deterrent, long-acting opioid analgesic... Read more

Phosphagenics Appoints Neura Therapeutik as US Strategic Commercial Advisors
August 1, 2012
Australian drug delivery technology company Phosphagenics Limited...Read more

Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities
July 23, 2012
Neura Therapeutik, LLC a privately-held specialty pharmaceutical company announced today the formation of...Read more

Neura Therapeutik is a specialty pharmaceutical company seeking to commercialize and develop innovative products addressing unmet needs for the treatment of pain.

Neura Therapeutik is forming commercial partnerships whereby Neura's domain expertise is leveraged to optimize the value of market ready assets through oversight and management of commercial activities; in-license analgesic assets where Neura's development and commercial experience can serve as a guide providing value enrichment through optimal clinical and commercial advancement; establish and maintain strategic partnerships providing synergy in commercial and development related activities allowing for Neura to remain a predominantly virtual company.